

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number
WO 2005/049836 A1

(51) International Patent Classification⁷: C12N 15/31,
A61K 39/118, 31/7088, A61P 31/04, C07H 21/00, C07K
14/295, 16/12, C12P 21/02, A61K 38/16

(21) International Application Number:
PCT/CA2004/002001

(22) International Filing Date:
19 November 2004 (19.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/481,690 21 November 2003 (21.11.2003) US

(71) Applicant (for all designated States except US): AVENTIS
PASTEUR LIMITED [CA/CA]; 1755 Steeles Ave West,
Toronto, Ontario M2R 3T4 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRUNHAM,
Robert, C. [CA/CA]; UBC Centre for Disease Control,
Medical Director BCCDCS, 655 W 12th Avenue, Van-
couver, BC V5Z 4R4 (CA). RAUDONIKIENE, Ausra
[CA/CA]; 7 Swiss Court, Toronto, Ontario M2M 4E2
(CA). GALLICHAN, Scott [CA/CA]; 1189 Britannia
Rd., Campbellville, Ontario L0P 1B0 (CA). MURDIN,
Andrew [GB/CA]; 11 Forest Hill Drive, Richmond Hill,
Ontario L4B 3C2 (CA).


(74) Agent: YACOOB, Reza, K.; 1755 Steeles Ave West,
Toronto, Ontario M2R 3T4 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

[Continued on next page]

(54) Title: IMMUNIZATION AGAINST *CHLAMYDIA* INFECTION

Protection from *C. trachomatis* Serovar D Challenge.



* Wilcoxon $p < .05$

(57) Abstract: The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically *C. trachomatis*. The method employs a vector containing a nucleotide sequence encoding a Mgp002 polypeptide of a strain of *Chlamydia* operably linked to a promoter to effect expression of the gene product in the host. Truncated forms of the full-length Mgp002 gene are useful immunogens for protecting against disease caused by infection with Chlamydia. The invention further provides recombinant Mgp002 protein useful for protecting against disease caused by infection with Chlamydia.



MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.